Neurocrine Biosciences Inc (NBIX)
141.36
-0.35
(-0.25%)
USD |
NASDAQ |
May 07, 10:55
Neurocrine Biosciences Gross Profit Margin (Quarterly): 98.54% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 98.54% |
December 31, 2023 | 98.35% |
September 30, 2023 | 97.75% |
June 30, 2023 | 97.46% |
March 31, 2023 | 97.98% |
December 31, 2022 | 98.13% |
September 30, 2022 | 98.43% |
June 30, 2022 | 98.73% |
March 31, 2022 | 98.52% |
December 31, 2021 | 98.69% |
September 30, 2021 | 98.58% |
June 30, 2021 | 98.93% |
March 31, 2021 | 98.77% |
December 31, 2020 | 98.83% |
Date | Value |
---|---|
September 30, 2020 | 98.96% |
June 30, 2020 | 99.21% |
March 31, 2020 | 99.11% |
December 31, 2019 | 98.98% |
September 30, 2019 | 99.01% |
June 30, 2019 | 99.13% |
March 31, 2019 | 99.21% |
December 31, 2018 | 98.82% |
September 30, 2018 | 98.98% |
June 30, 2018 | 99.12% |
March 31, 2018 | 98.66% |
December 31, 2017 | 99.20% |
September 30, 2017 | 99.29% |
June 30, 2017 | 99.04% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
97.46%
Minimum
Jun 2023
99.21%
Maximum
Jun 2020
98.60%
Average
98.71%
Median
Gross Profit Margin (Quarterly) Benchmarks
Globus Medical Inc | 56.94% |
Inspire Medical Systems Inc | 85.43% |
AIM ImmunoTech Inc | 81.54% |
Protalix BioTherapeutics Inc | 15.54% |
Armata Pharmaceuticals Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Equity | 18.20% |
Return on Assets | 12.71% |
Return on Invested Capital | 16.66% |
Profit Margin (Quarterly) | 8.42% |
Operating Margin (Quarterly) | 20.43% |
Return on Net Operating Assets | 51.71% |